Aqilion publishes Annual Report for 2023

AQILION AB (publ) hereby announces that the Swedish version of the 2023 Annual Report has been published.

The Annual Report, which is attached in Swedish, can also be downloaded from the company’s website. An English translation of the Annual Report will be available on the website no later than the week commencing May 20, 2024.

For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.

We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The ideas that we choose are based on solid scientific grounds, where we, with reasonable assumptions, can understand the underlying biology, clinical relevance and patient benefit.

The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion runs its development programs in a partly virtual organization in close collaboration with selected partners with specific expertise in drug development.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com

Tags: